# Udgivne artikler, førsteforfatter

Al-Mashhadi Z, Viggers R, Linde JS, Vestergaard P, Gregersen S. **SGLT2 inhibitor treatment does not increase risk of osteoporotic fractures compared to GLP-1 receptor agonists: A Danish population-based cohort study**. Endocrine Abstracts, vol. 81, Presented at European Congress of Endocrinology 2022, Milano, Italy: BioScientifica Ltd.; 2022. <https://doi.org/10.1530/endoabs.81.OC8.2>.

Al-Mashhadi ZK, Viggers R, Fuglsang-Nielsen R, Vestergaard P, Gregersen S, Starup-Linde J. **The risk of major osteoporotic fractures with GLP-1 receptor agonists when compared to DPP-4 inhibitors: A Danish nationwide cohort study**. Frontiers in Endocrinology 2022;13. <https://doi.org/10.3389/fendo.2022.882998>.

Al-Mashhadi Z, Viggers R, Fuglsang-Nielsen R, de Vries F, van den Bergh JP, Harsløf T, Langdahl B, Gregersen S, Starup-Linde J. **Glucose-Lowering Drugs and Fracture Risk—a Systematic Review**. Current Osteoporosis Reports 2020;18:737–58. <https://doi.org/10.1007/s11914-020-00638-8>.

Al-Mashhadi Z, Viggers R, Fuglsang-Nielsen R, Langdahl BL, Vestergaard P, Gregersen S, Linde JS. **Bone Health in the Elderly with Type 2 Diabetes Mellitus: A Systematic Review**. OBM Geriatrics 2020;4. <https://doi.org/10.21926/obm.geriatr.2002123>.

# Udgivne artikler, medforfatter

Al-Mashhadi RH, Tolbod LP, Bloch LØ, Bjørklund MM, Nasr ZP, Al-Mashhadi Z, Winterdahl M, Frøkiær J, Falk E, Bentzon JF. **18Fluorodeoxyglucose Accumulation in Arterial Tissues Determined by PET Signal Analysis**. Journal of the American College of Cardiology 2019;74:1220–32. <https://doi.org/10.1016/j.jacc.2019.06.057>.

Al-Mashhadi RH, Al-Mashhadi AL, Nasr ZP, Mortensen MB, Lewis EA, Camafeita E, Ravlo K, Al-Mashhadi Z, Kjær DW, Palmfeldt J, Bie P, Jensen JM, Nørgaard BL, Falk E, Vázquez J, Bentzon JF. **Local Pressure Drives Low-Density Lipoprotein Accumulation and Coronary Atherosclerosis in Hypertensive Minipigs**. Journal of the American College of Cardiology 2021;77:575–89. <https://doi.org/10.1016/j.jacc.2020.11.059>.

Viggers R, Al-Mashhadi Z, Fuglsang-Nielsen R, Gregersen S, Starup-Linde J. **The Impact of Exercise on Bone Health in Type 2 Diabetes Mellitus—a Systematic Review**. Current Osteoporosis Reports 2020;18:357–70. <https://doi.org/10.1007/s11914-020-00597-0>.

Viggers R, Al-Mashhadi Z, Starup-Linde J, Vestergaard P. **Alendronate Use and Risk of Type 2 Diabetes: A Nationwide Danish Nested Case-Control Study**. Frontiers in Endocrinology 2021;12. <https://doi.org/10.3389/fendo.2021.771426>.

Viggers R, Al-Mashhadi Z, Starup-Linde J, Vestergaard P. **The Efficacy of Alendronate Versus Denosumab on Major Osteoporotic Fracture Risk in Elderly Patients With Diabetes Mellitus: A Danish Retrospective Cohort Study**. Frontiers in Endocrinology 2022;12. <https://doi.org/10.3389/fendo.2021.826997>.

van Hulten V, Driessen JHM, Starup-Linde JK, Al-Mashhadi ZK, Viggers R, Klungel OH, Souverein PC, Vestergaard P, Stehouwer CDA, van den Bergh JP. **The associations of sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors as add-on to metformin with fracture risk in patients with type 2 diabetes mellitus**. Diabetes, Obesity and Metabolism 2023;25:3235–47. <https://doi.org/10.1111/dom.15220>.

Mellbye FD, Nguyen MD, Hermansen K, Jeppesen PB, Al-Mashhadi ZK, Ringgaard S, Gregersen S. **Effects of 12-Week Supplementation with Coffee Diterpene Cafestol in Healthy Subjects with Increased Waist Circumference: A Randomized, Placebo-Controlled Trial**. Nutrients 2024;16. <https://doi.org/10.3390/nu16193232>.

Starup-Linde J, Westberg-Rasmussen S, Viggers R, Al-Mashhadi ZK, Handberg A, Vestergaard P, Gregersen S. **Serum osteoglycin is stable during various glycemic challenges in healthy men**. Endocrine 2024;85:1117–21. <https://doi.org/10.1007/s12020-024-03789-1>.

# Konferenceabstrakts

Al-Mashhadi ZK, Viggers R, Fuglsang-Nielsen R, Vestergaard P, Gregersen S, Starup-Linde J. **Fracture risk in treatment with GLP-1RA compared to DPP-4i: A Danish nationwide cohort study**. Diabetologia, vol. 65, suppl. 1, Abstract no. 351, Presented at 58th EASD Annual Meeting of the European Association for the Study of Diabetes, Stockholm, Sweden: Springer; 2022, p. S183.

Al-Mashhadi Z, Viggers R, Linde JS, Vestergaard P, Gregersen S. **SGLT2 inhibitor treatment does not increase risk of osteoporotic fractures compared to GLP-1 receptor agonists: A Danish population-based cohort study**. Endocrine Abstracts, vol. 81, Presented at European Congress of Endocrinology 2022, Milano, Italy: BioScientifica Ltd.; 2022. <https://doi.org/10.1530/endoabs.81.OC8.2>.

# Manuskripter under udarbejdelse

Al-Mashhadi ZK, Viggers R, Starup-Linde J, Langdahl BL, van Hulten V, van den Bergh JP, Driessen J, Vestergaard P, Gregersen S. **Systemic glucocorticoid use increases fracture risk equally in those with and without type 2 diabetes mellitus: A Danish nationwide cohort study** n.d.